LIVIVO - Search results -

Search results

Result 1 - 10 of total 179

Search options

Article ; Online: How Useful is COVID-19 Antibody Testing - A Current Assessment for Oncologists.

Maple, P A C / Sikora, K

Clinical oncology (Royal College of Radiologists (Great Britain))

2020 Volume 33, Issue 1, Page(s) e73–e81

Abstract: The coronavirus disease 2019 (COVID-19) pandemic due to infection by a new human coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has seriously disrupted the provision of oncology services and their uptake. Antibody testing, ... ...

Abstract	The coronavirus disease 2019 (COVID-19) pandemic due to infection by a new human coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has seriously disrupted the provision of oncology services and their uptake. Antibody testing, both at an individual level and of populations, has been widely viewed to be a key activity for guiding the options for treatment of high-risk individuals, as well as the implementation of safe control of infection measures. Ideally, the detection of a specific antibody should signify that all individuals tested have been infected by SARS-CoV-2 and that in the case of specific IgG that they are immune to further infection. This would enable SARS-CoV-2-infected individuals to be appropriately managed and healthcare workers shown to be immune to return to work where they would no longer pose a risk to their patients or be at risk themselves. Unfortunately, this is not the case for COVID-19, where it has been shown that immunity may not be protective, and seroconversion delayed or absent. The variability in antibody test performance, particularly that of lateral flow assays, has caused confusion for the public and healthcare professions alike. Many antibody test devices have been made available without independent evaluations and these may lack both adequate sensitivity and specificity. This review seeks to educate healthcare workers, particularly those working in oncology, of the current benefits and limitations of SARS-CoV-2 antibody testing.
MeSH term(s)	COVID-19/immunology ; COVID-19 Serological Testing/methods ; COVID-19 Serological Testing/standards ; Humans ; Immunoassay/methods ; Immunoassay/standards ; Male ; Occupational Health/standards ; Oncologists ; SARS-CoV-2/immunology ; Sensitivity and Specificity
Language	English
Publishing date	2020-10-13
Publishing country	England
Document type	Journal Article
ZDB-ID	1036844-9
ISSN	1433-2981 ; 0936-6555
ISSN (online)	1433-2981
ISSN	0936-6555
DOI	10.1016/j.clon.2020.10.008
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2774: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: How Useful is COVID-19 Antibody Testing – A Current Assessment for Oncologists

Maple, P.A.C. / Sikora, K.

Clinical Oncology ; ISSN 0936-6555

2020

Keywords	Oncology ; Radiology Nuclear Medicine and imaging ; covid19
Language	English
Publisher	Elsevier BV
Publishing country	us
Document type	Article ; Online
DOI	10.1016/j.clon.2020.10.008
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: How Useful is COVID-19 Antibody Testing – a Current Assessment for Oncologists

Maple, P. A. C. / Sikora, K.

Clinical Oncology

Abstract	The coronavirus disease 2019 (COVID-19) pandemic due to infection by a new human coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has seriously disrupted the provision of oncology services and their uptake Antibody testing, both at an individual level and of populations, has been widely viewed to be a key activity for guiding the options for treatment of high-risk individuals, as well as the implementation of safe control of infection measures Ideally, the detection of a specific antibody should signify that all individuals tested have been infected by SARS-CoV-2 and that in the case of specific IgG that they are immune to further infection This would enable SARS-CoV-2-infected individuals to be appropriately managed and healthcare workers shown to be immune to return to work where they would no longer pose a risk to their patients or be at risk themselves Unfortunately, this is not the case for COVID-19, where it has been shown that immunity may not be protective, and seroconversion delayed or absent The variability in antibody test performance, particularly that of lateral flow assays, has caused confusion for the public and healthcare professions alike Many antibody test devices have been made available without independent evaluations and these may lack both adequate sensitivity and specificity This review seeks to educate healthcare workers, particularly those working in oncology, of the current benefits and limitations of SARS-CoV-2 antibody testing
Keywords	covid19
Publisher	WHO
Document type	Article
Note	WHO #Covidence: #856571
Database	COVID19

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾

Article ; Online: Population (Antibody) Testing for COVID-19—Technical Challenges, Application and Relevance, an English Perspective

Peter A. C. Maple

Vaccines, Vol 9, Iss 550, p

2021 Volume 550

Abstract: In the UK, population virus or antibody testing using virus swabs, serum samples, blood spots or oral fluids has been performed to a limited extent for several diseases including measles, mumps, rubella and hepatitis and HIV. The collection of population- ...

Abstract	In the UK, population virus or antibody testing using virus swabs, serum samples, blood spots or oral fluids has been performed to a limited extent for several diseases including measles, mumps, rubella and hepatitis and HIV. The collection of population-based infection and immunity data is key to the monitoring of disease prevalence and assessing the effectiveness of interventions such as behavioural modifications and vaccination. In particular, the biological properties of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and its interaction with the human host have presented several challenges towards the development of population-based immunity testing. Measuring SARS-CoV-2 immunity requires the development of antibody assays of acceptable sensitivity and specificity which are capable of accurately detecting seroprevalence and differentiating protection from non-protective responses. Now that anti-COVID-19 vaccines are becoming available there is a pressing need to measure vaccine efficacy and the development of herd immunity. The unprecedented impact of the SARS-CoV-2 pandemic in the UK in terms of morbidity, mortality, and economic and social disruption has mobilized a national scientific effort to learn more about this virus. In this article, the challenges of testing for SARS-CoV-2 infection, particularly in relation to population-based immunity testing, will be considered and examples given of relevant national level studies.
Keywords	COVID-19 ; SARS-CoV-2 ; antibodies ; immunity ; seroepidemiology ; England ; Medicine ; R
Subject code	360
Language	English
Publishing date	2021-05-01T00:00:00Z
Publisher	MDPI AG
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Book ; Online: SaGess

Limnios, Stratis / Selvaraj, Praveen / Cucuringu, Mihai / Maple, Carsten / Reinert, Gesine / Elliott, Andrew

Sampling Graph Denoising Diffusion Model for Scalable Graph Generation

2023

Abstract: Over recent years, denoising diffusion generative models have come to be considered as state-of-the-art methods for synthetic data generation, especially in the case of generating images. These approaches have also proved successful in other applications ...

Abstract	Over recent years, denoising diffusion generative models have come to be considered as state-of-the-art methods for synthetic data generation, especially in the case of generating images. These approaches have also proved successful in other applications such as tabular and graph data generation. However, due to computational complexity, to this date, the application of these techniques to graph data has been restricted to small graphs, such as those used in molecular modeling. In this paper, we propose SaGess, a discrete denoising diffusion approach, which is able to generate large real-world networks by augmenting a diffusion model (DiGress) with a generalized divide-and-conquer framework. The algorithm is capable of generating larger graphs by sampling a covering of subgraphs of the initial graph in order to train DiGress. SaGess then constructs a synthetic graph using the subgraphs that have been generated by DiGress. We evaluate the quality of the synthetic data sets against several competitor methods by comparing graph statistics between the original and synthetic samples, as well as evaluating the utility of the synthetic data set produced by using it to train a task-driven model, namely link prediction. In our experiments, SaGess, outperforms most of the one-shot state-of-the-art graph generating methods by a significant factor, both on the graph metrics and on the link prediction task.
Keywords	Computer Science - Machine Learning
Subject code	004
Publishing date	2023-06-29
Publishing country	us
Document type	Book ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Cytomegalovirus and Epstein–Barr Virus Associations with Neurological Diseases and the Need for Vaccine Development

Peter A. C. Maple

Vaccines, Vol 8, Iss 1, p

2020 Volume 35

Abstract: Herpesviruses have been isolated from a wide range of hosts including humans—for which, nine species have been designated. The human herpesviruses are highly host adapted and possess the capacity for latency, allowing them to survive in the host for life, ...

Abstract	Herpesviruses have been isolated from a wide range of hosts including humans—for which, nine species have been designated. The human herpesviruses are highly host adapted and possess the capacity for latency, allowing them to survive in the host for life, effectively hidden from the immune system. This ability of human herpesviruses to modulate the host immune response poses particular challenges for vaccine development but at the same time proves attractive for the application of human herpesvirus vaccines to certain spheres of medicine. In this review, congenital cytomegalovirus (CMV) infection and hearing loss will be described followed by a comment on the status of current vaccine development. Secondly, the association of Epstein−Barr virus (EBV) infection with multiple sclerosis (MS) and how EBV vaccination may be of benefit will then be discussed. Prevention of congenital CMV by vaccination is an attractive proposition and several vaccines have been evaluated for potential use. Particularly challenging for the development of CMV vaccines are the needs to prevent primary infection, reinfection, and reactivation at the same time as overcoming the capacity of the virus to generate highly sophisticated immunomodulatory mechanisms. Cost and the practicalities of administering potential vaccines are also significant issues, particularly for low- and middle-income countries, where the burden of disease is greatest. An effective EBV vaccine that could prevent the 200,000 new EBV-associated malignancies which occur globally each year is not currently available. There is increasing interest in developing EBV vaccines to prevent MS and, in view of the association of infectious mononucleosis with MS, reducing childhood infectious mononucleosis is a potential intervention. Currently, there is no licensed EBV vaccine and, in order to progress the development of EBV vaccines for preventing MS, a greater understanding of the association of EBV with MS is required.
Keywords	epstein–barr virus ; cytomegalovirus ; multiple sclerosis ; congenital infection ; Medicine ; R
Subject code	610
Language	English
Publishing date	2020-01-01T00:00:00Z
Publisher	MDPI AG
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Correction: Developing an integrated clinical decision support system for the early identification and management of kidney disease-building cross-sectoral partnerships.

Gorham, Gillian / Abeyaratne, Asanga / Heard, Sam / Moore, Liz / George, Pratish / Kamler, Paul / Majoni, Sandawana William / Chen, Winnie / Balasubramanya, Bhavya / Talukder, Mohammad Radwanur / Pascoe, Sophie / Whitehead, Adam / Sajiv, Cherian / Maple-Brown, Louise / Kangaharan, Nadarajah / Cass, Alan

BMC medical informatics and decision making

2024 Volume 24, Issue 1, Page(s) 89

Language	English
Publishing date	2024-03-28
Publishing country	England
Document type	Published Erratum
ZDB-ID	2046490-3
ISSN	1472-6947 ; 1472-6947
ISSN (online)	1472-6947
ISSN	1472-6947
DOI	10.1186/s12911-024-02492-5
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Developing an integrated clinical decision support system for the early identification and management of kidney disease-building cross-sectoral partnerships.

BMC medical informatics and decision making

2024 Volume 24, Issue 1, Page(s) 69

Abstract: Background: The burden of chronic conditions is growing in Australia with people in remote areas experiencing high rates of disease, especially kidney disease. Health care in remote areas of the Northern Territory (NT) is complicated by a mobile ... ...

Abstract	Background: The burden of chronic conditions is growing in Australia with people in remote areas experiencing high rates of disease, especially kidney disease. Health care in remote areas of the Northern Territory (NT) is complicated by a mobile population, high staff turnover, poor communication between health services and complex comorbid health conditions requiring multidisciplinary care. Aim: This paper aims to describe the collaborative process between research, government and non-government health services to develop an integrated clinical decision support system to improve patient care. Methods: Building on established partnerships in the government and Aboriginal Community-Controlled Health Service (ACCHS) sectors, we developed a novel digital clinical decision support system for people at risk of developing kidney disease (due to hypertension, diabetes, cardiovascular disease) or with kidney disease. A cross-organisational and multidisciplinary Steering Committee has overseen the design, development and implementation stages. Further, the system's design and functionality were strongly informed by experts (Clinical Reference Group and Technical Working Group), health service providers, and end-user feedback through a formative evaluation. Results: We established data sharing agreements with 11 ACCHS to link patient level data with 56 government primary health services and six hospitals. Electronic Health Record (EHR) data, based on agreed criteria, is automatically and securely transferred from 15 existing EHR platforms. Through clinician-determined algorithms, the system assists clinicians to diagnose, monitor and provide guideline-based care for individuals, as well as service-level risk stratification and alerts for clinically significant events. Conclusion: Disconnected health services and separate EHRs result in information gaps and a health and safety risk, particularly for patients who access multiple health services. However, barriers to clinical data sharing between health services still exist. In this first phase, we report how robust partnerships and effective governance processes can overcome these barriers to support clinical decision making and contribute to holistic care.
MeSH term(s)	Humans ; Decision Support Systems, Clinical ; Delivery of Health Care ; Northern Territory ; Hospitals ; Risk Assessment
Language	English
Publishing date	2024-03-08
Publishing country	England
Document type	Journal Article
ZDB-ID	2046490-3
ISSN	1472-6947 ; 1472-6947
ISSN (online)	1472-6947
ISSN	1472-6947
DOI	10.1186/s12911-024-02471-w
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Efficient, multi-hundred-gram scale access to E3 ubiquitin ligase ligands for degrader development.

Cooper, Mark S / Norley, Mark C / Armitage, Simon / Cresser-Brown, Joel O / Edmonds, Anthony K / Goggins, Sean / Hopewell, Jonathan P / Karadogan, Burhan / Knights, Kevin A / Nash, Toby J / Oakes, Catherine S / O'Neill, William J / Pridmore, Simon J / Maple, Hannah J / Marsh, Graham P

Organic & biomolecular chemistry

2023 Volume 21, Issue 41, Page(s) 8344–8352

Abstract: Small molecule heterobifunctional degraders (commonly also known as PROTACs) offer tremendous potential to deliver new therapeutics in areas of unmet medical need. To deliver on this promise, a new discipline directed at degrader design and optimization ... ...

Abstract	Small molecule heterobifunctional degraders (commonly also known as PROTACs) offer tremendous potential to deliver new therapeutics in areas of unmet medical need. To deliver on this promise, a new discipline directed at degrader design and optimization has emerged within medicinal chemistry to address a central challenge, namely how to optimize relatively large, heterobifunctional molecules for activity, whilst maintaining drug-like properties. This process involves simultaneous optimization of the three principle degrader components: E3 ubiquitin ligase ligand, linker, and protein of interest (POI) ligand. A substantial degree of commonality exists with the E3 ligase ligands typically used at the early stages of degrader development, resulting in demand for these compounds as chemical building blocks in degrader research programs. We describe herein a collation of large scale, high-yielding syntheses to access the most utilized E3 ligase ligands to support early-stage degrader development.
MeSH term(s)	Ubiquitin-Protein Ligases/metabolism ; Proteolysis ; Ligands ; Proteins/metabolism
Chemical Substances	Ubiquitin-Protein Ligases (EC 2.3.2.27) ; Ligands ; Proteins
Language	English
Publishing date	2023-10-25
Publishing country	England
Document type	Journal Article
ZDB-ID	2097583-1
ISSN	1477-0539 ; 1477-0520
ISSN (online)	1477-0539
ISSN	1477-0520
DOI	10.1039/d3ob00983a
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Two rare forms of congenital adrenal hyperplasia, 11β hydroxylase deficiency and 17-hydroxylase/17,20-lyase deficiency, presenting with novel mutations.

Bulsari, Krupali / Maple-Brown, Louise / Falhammar, Henrik

Hormones (Athens, Greece)

2018 Volume 17, Issue 1, Page(s) 127–132

Abstract: ... c.954G > A [p.Thr318Thr]) on one of the alleles and a novel mutation, R123G (c.367C > G [p.Arg123Gly ... characteristics. She was heterozygous for a previously recognized mutation, R125Q (c.374G > A [p.Arg125Gln]), and ... a novel single base-pair deletion, G337fs (c.1010delG [p.Gly337Valfs*82]), which creates a frameshift ...

Abstract	Background: Congenital adrenal hyperplasia (CAH) is a rare autosomal recessive disorder caused by deficiency of various enzymes responsible for adrenal steroidogenesis. 11-Beta-hydroxylase deficiency (11βOHD) and 17-hydroxylase/17,20-lyase deficiency (17OHD) are rare causes of CAH. Methods/results: We hereby present a 65-year-old man with 11βOHD and a 33-year-old woman with 17OHD. The man with 11βOHD presented with peripheral precocious puberty and hypertension at age 15 years, fathered two children but developed complications of chronic glucocorticoid therapy on long-term follow-up. Interestingly, his younger sister had been diagnosed with the same condition at age 19 and had later given birth to four children while on glucocorticoids. Exome sequencing of the CYP11B1 gene detected the previously reported pathogenic mutation T318T (c.954G > A [p.Thr318Thr]) on one of the alleles and a novel mutation, R123G (c.367C > G [p.Arg123Gly]), on the other in a highly conserved region of the CYP11B1 gene. The woman with 17OHD presented with severe hypokalemia at age 22 years against a background of primary amenorrhea and lack of development of secondary sexual characteristics. She was heterozygous for a previously recognized mutation, R125Q (c.374G > A [p.Arg125Gln]), and a novel single base-pair deletion, G337fs (c.1010delG [p.Gly337Valfs82]), which creates a frameshift with a new stop codon in the last exon of the gene, making it a likely pathogenic variant. Conclusion:* Recognition of novel mutations is clinically significant and will contribute to the understanding of the phenotype-genotype relationship of these rare disorders in the future. It also highlights successful fertility outcomes in 11βOHD which have not been well documented in the literature so far.
MeSH term(s)	Adrenal Hyperplasia, Congenital/genetics ; Adult ; Aged ; Exons ; Female ; Fertility/genetics ; Humans ; Male ; Mutation ; Steroid 11-beta-Hydroxylase/genetics ; Steroid 17-alpha-Hydroxylase/genetics
Chemical Substances	Steroid 17-alpha-Hydroxylase (EC 1.14.14.19) ; Steroid 11-beta-Hydroxylase (EC 1.14.15.4)
Language	English
Publishing date	2018-04-16
Publishing country	Switzerland
Document type	Case Reports ; Journal Article
ZDB-ID	2581819-3
ISSN	2520-8721 ; 1109-3099
ISSN (online)	2520-8721
ISSN	1109-3099
DOI	10.1007/s42000-018-0006-8
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito